BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, Ochs S, Rizzani A, Meier D, Thasler WE, Hanenberg H, De Toni EN, Bassermann F, Schäfer C, Göke B, Schindler D, Gallmeier E. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 2010;9:127. [PMID: 20509860 DOI: 10.1186/1476-4598-9-127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Cimino GD, Pan CX, Henderson PT. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 2013;5:369-91. [PMID: 23394702 DOI: 10.4155/bio.12.325] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
2 Su WP, Hsu SH, Wu CK, Chang SB, Lin YJ, Yang WB, Hung JJ, Chiu WT, Tzeng SF, Tseng YL, Chang JY, Su WC, Liaw H. Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. Oncotarget 2014;5:6323-37. [PMID: 25051366 DOI: 10.18632/oncotarget.2210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Qi J, Zhou J, Tang XQ, Wang Y. Gene Biomarkers Derived from Clinical Data of Hepatocellular Carcinoma. Interdiscip Sci 2020;12:226-36. [PMID: 32297074 DOI: 10.1007/s12539-020-00366-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Xiong T, Chen X, Wei H, Xiao H. Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells. Arch Med Sci 2015;11:301-6. [PMID: 25995744 DOI: 10.5114/aoms.2014.43164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Ferroudj S, Yildiz G, Bouras M, Iscan E, Ekin U, Ozturk M. Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance: BRCA1 and liver cancer chemoresistance. Hepatol Res 2016;46:1264-74. [DOI: 10.1111/hepr.12675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
6 Choi C, Son A, Lee GH, Shin SW, Park S, Ahn SH, Chung Y, Yu JI, Park HC. Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction. PLoS One 2019;14:e0218049. [PMID: 31194786 DOI: 10.1371/journal.pone.0218049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Valeri A, Martínez S, Casado JA, Bueren JA. Fanconi anaemia: from a monogenic disease to sporadic cancer. Clin Transl Oncol. 2011;13:215-221. [PMID: 21493181 DOI: 10.1007/s12094-011-0645-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, Spitz MR, Wei Q. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011;29:4121-8. [PMID: 21947825 DOI: 10.1200/JCO.2010.34.3616] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
9 Su WP, Ho YC, Wu CK, Hsu SH, Shiu JL, Huang JC, Chang SB, Chiu WT, Hung JJ, Liu TL, Wu WS, Wu PY, Su WC, Chang JY, Liaw H. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Sci Rep 2017;7:3879. [PMID: 28634400 DOI: 10.1038/s41598-017-04223-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Anderson MG, Zhang Q, Rodriguez LE, Hecquet CM, Donawho CK, Ansell PJ, Reilly EB. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer 2021;21:681. [PMID: 34107902 DOI: 10.1186/s12885-021-08403-5] [Reference Citation Analysis]
11 Hucl T, Gallmeier E. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res 2011;60:453-65. [PMID: 21401292 DOI: 10.33549/physiolres.932115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
12 Taylor SJ, Arends MJ, Langdon SP. Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer. Exploration of Targeted Anti-tumor Therapy 2020;1:26-52. [DOI: 10.37349/etat.2020.00003] [Reference Citation Analysis]
13 Ueda F, Sumi K, Tago K, Kasahara T, Funakoshi-tago M. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs. Cellular Signalling 2013;25:2115-24. [DOI: 10.1016/j.cellsig.2013.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
14 Martínez S, Pérez L, Galmarini CM, Aracil M, Tercero JC, Gago F, Albella B, Bueren JA. Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. Br J Pharmacol 2013;170:871-82. [PMID: 23937566 DOI: 10.1111/bph.12331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
15 Papachristou F, Anninou N, Koukoulis G, Paraskakis S, Sertaridou E, Tsalikidis C, Pitiakoudis M, Simopoulos C, Tsaroucha A. Differential effects of cisplatin combined with the flavonoid apigenin on HepG2, Hep3B, and Huh7 liver cancer cell lines. Mutat Res 2021;866:503352. [PMID: 33985696 DOI: 10.1016/j.mrgentox.2021.503352] [Reference Citation Analysis]
16 Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL; CiRCE Study Group. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget 2017;8:62842-57. [PMID: 28968953 DOI: 10.18632/oncotarget.11327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Revie D, Salahuddin SZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J 2011;8:346. [PMID: 21745397 DOI: 10.1186/1743-422X-8-346] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
18 Baek SJ, Whitlock NC. Molecular Targets of Resveratrol in Carcinogenesis. In: Cho WC, editor. Evidence-based Anticancer Materia Medica. Dordrecht: Springer Netherlands; 2011. pp. 319-47. [DOI: 10.1007/978-94-007-0526-5_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]